https://klse.i3investor.com/blogs/changwt/2020-11-
Post# of 36519
![](/assets/46931549/no_avatar_available_thumb.jpg)
“The results of the ex-vivo human blood screen to date are very encouraging, with demonstrated T helper cell activation, no Th2 response, and positive antibody binding in serum. Through targeted immune system regulation, we are developing the Ii-Key COVID vaccine as a "Complete Vaccine" that activates both the cellular and humoral (antibody) responses to provide long-term immune memory for protection from SARS-CoV-2 infection and COVID-19.”
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)